Aimed Bio

0009K0 · KOSDAQ · ₩0009K0 · 에임드바이오

₩20,850▲ ₩300 (1.46%)End-of-day · Oct 28, 2026 · End-of-day prices.
Trade
Alert me

Valuation model · Discounted cash flow (DCF)

We use a 5-year discounted cash flow: the value of the cash the business is expected to produce, in today's money.

Fair value per share

₩5,936

vs the current price (₩20,850)

Enterprise value
₩296B
Equity value
₩387B
WACC
7.4%

Model estimate based on the assumptions shown. Not a price target and not a buy or sell signal. This is not financial advice.

Why the model and the price differ

The model is 72% away from today's price. A gap this size usually means the market expects something the past figures don't show yet, or the model leaves something out. What we can see:

  • No operating margin up to 90% gets the model to today's price at these growth assumptions.
  • Or revenue growth +37.7 points a year higher than assumed in each of the 5 years.

Treat the model as a starting point: change the assumptions to the story you believe, and compare with the multiples check below.

Bear / Base / Bull

Bear
₩4,600
−77.9%
Base
₩5,936
−71.5%
Bull
₩8,061
−61.3%

Bear: revenue growth 3 points lower every year, EBIT margin 2 points lower, WACC 1 point higher. Bull: the opposite.

Assumptions

Sign in to change the assumptions and see the results update. Sign in

Cycle options

Margin path

Every year uses the cycle-average margin (43.9%).

Revenue growth

  • 3%

    How much sales grow that year, compared with the year before.

    Default: not enough revenue history, so 3%.

  • 3%

    How much sales grow that year, compared with the year before.

    Default: not enough revenue history, so 3%.

  • 3%

    How much sales grow that year, compared with the year before.

    Default: not enough revenue history, so 3%.

  • 3%

    How much sales grow that year, compared with the year before.

    Default: not enough revenue history, so 3%.

  • 3%

    How much sales grow that year, compared with the year before.

    Default: not enough revenue history, so 3%.

Business

  • 43.9%

    Operating profit as a share of revenue.

    Default: through-the-cycle average of the last 12 months and the last 1 annual reports' operating margins.

  • 27.5%

    Share of operating profit paid as corporate tax.

    Default: Korea's top corporate tax rate (25%) plus 10% local income tax.

  • 0.6%

    The non-cash cost of wearing out equipment, added back to cash flow (% of revenue).

    Default: not in the statements, so 80% of capital spending (most spending replaces equipment that wears out).

  • 0.8%

    Money spent on factories, equipment, software and other long-term assets (% of revenue).

    Default: average of the last 1 annual reports (cash flow statements; equipment and intangibles).

  • 5.7%

    Stock and unpaid customer bills, less unpaid supplier bills, as a % of revenue. Each year's extra revenue ties up this much more cash.

    Default: working capital (current assets less cash and deposits, minus current liabilities other than borrowings) as a share of revenue, averaged over the last 1 years.

Discount rate

  • 2%

    How fast cash flows keep growing every year after year 5.

    Default: about Korea's long-run inflation plus real growth.

  • 4.08%

    Yield on Korea's 10-year government bond: the return with almost no risk.

    Default: Korea Treasury Bond 10-year yield on 2026-10-29.

  • 0.6

    How much the share moves when the market moves: 1 means just like the market.

    Default: 47 weeks of weekly returns against KOSPI (official index); raw beta 0.09, adjusted toward 1 and kept between 0.6 and 2.0.

  • 5.5%

    The extra return investors want for owning shares instead of bonds.

    Default: a typical premium for Korean shares.

  • 5.58%

    The interest rate the company would pay to borrow.

    Default: the 10-year yield plus a 1.5% credit spread.

Starting point

Revenue (TTM to H1 2026)
₩47B
Net debt (borrowings and leases − cash and deposits)
−₩91B
− Minority interests
₩2.4M
Shares
65,137,661
Share price
₩20,850
Market cap
₩1.4T

TTM = trailing 12 months: the last four reported quarters added together. "TTM to H1 2026" is the 12 months up to the latest quarterly or half-year report (H1 = to the end of June). Year 1 grows from there.

Past years and projection

Grey columns are reported results from the annual reports (after-tax EBIT at the model's tax rate), so you can check the growth and margin assumptions against the past. Years 1–5 are the model.

FY2025Year 1Year 2Year 3Year 4Year 5
Revenue₩47B₩49B₩50B₩52B₩53B₩55B
Growth—3.0%3.0%3.0%3.0%3.0%
EBIT₩21B₩21B₩22B₩23B₩23B₩24B
EBIT margin43.9%43.9%43.9%43.9%43.9%43.9%
After-tax EBIT₩15B₩15B₩16B₩16B₩17B₩17B
+ Depreciation—₩292M₩301M₩310M₩319M₩329M
− Capital spending₩363M₩390M₩401M₩413M₩426M₩438M
− Working capital—₩81M₩83M₩86M₩88M₩91M
Free cash flow—₩15B₩16B₩16B₩17B₩17B
Discount factor—0.9310.8670.8080.7520.700
Present value—₩14B₩14B₩13B₩13B₩12B

Terminal value ₩329B, worth ₩230B today: 78% of enterprise value. It assumes spending settles at 110% of depreciation once growth slows to the terminal rate.

Sensitivity

Fair value per share as two inputs change; the middle is the current case.

WACC ↓ · Terminal growth →1.0%1.5%2.0%2.5%3.0%
6.4%₩6,104₩6,497₩6,979₩7,586₩8,373
6.9%₩5,699₩6,019₩6,404₩6,878₩7,473
7.4%₩5,358₩5,623₩5,936₩6,314₩6,778
7.9%₩5,067₩5,288₩5,548₩5,855₩6,226
8.4%₩4,815₩5,003₩5,220₩5,475₩5,776

Now (TTM)

Market cap
₩1.4T
Enterprise value
₩1.3T
P/E
270.4×
P/B
6.6×
P/S
28.7×
EV/EBITDA
—
Dividend yield
0.0%

Over time (at each year end)

2025
Price₩57,600
Market cap₩3.8T
P/E747.0×
P/B19.5×
P/S79.4×
EV/EBITDA—
Dividend yield0.0%

Versus similar companies

CompanyP/EP/BP/SEV/EBITDADividend yield
Aimed Bio270.4×6.6×28.7×—0.0%
Samsung Biologics32.0×7.6×14.0×—0.0%
Celltrion27.9×2.5×9.0×—0.0%
Alteogen80.5×29.0×61.2×—0.1%
SK biopharmaceuticals14.7×5.8×6.8×—0.0%
Yuhan24.0×2.4×2.5×31.3×0.8%
HLB—15.7×55.6×—0.0%
Similar companies (median)27.9×6.7×11.5×31.3×0.0%

Calculated from end-of-day prices and filed financial statements. Not a recommendation. This is not financial advice.

Also known as: Aimed Bio / 에임드바이오 / 0009K0 / KRX:0009K0

Source: KRX statistical information